The Clostridioides difficile Infections (Clostridium difficile Associated Disease) drugs in development market research report provides comprehensive information on the therapeutics under development for Clostridioides difficile Infections (Clostridium difficile Associated Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Clostridioides difficile Infections (Clostridium difficile Associated Disease). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Clostridioides difficile Infections (Clostridium difficile Associated Disease) and features dormant and discontinued products.
GlobalData tracks 87 drugs in development for Clostridioides difficile Infections (Clostridium difficile Associated Disease) by 76 companies/universities/institutes. The top development phase for Clostridioides difficile Infections (Clostridium difficile Associated Disease) is preclinical with 37 drugs in that stage. The Clostridioides difficile Infections (Clostridium difficile Associated Disease) pipeline has 75 drugs in development by companies and 12 by universities/ institutes. Some of the companies in the Clostridioides difficile Infections (Clostridium difficile Associated Disease) pipeline products market are: Fzata, Theriva Biologics and Micropharm.
The key targets in the Clostridioides difficile Infections (Clostridium difficile Associated Disease) pipeline products market include Clostridium difficile Toxin B (toxB or EC 3.4.22.), Clostridium difficile Toxin A (toxA or EC 3.4.22.), and DNA.
The key mechanisms of action in the Clostridioides difficile Infections (Clostridium difficile Associated Disease) pipeline product include Clostridium difficile Toxin B (toxB or EC 3.4.22.) Inhibitor with 13 drugs in Phase II. The Clostridioides difficile Infections (Clostridium difficile Associated Disease) pipeline products include six routes of administration with the top ROA being Oral and 13 key molecule types in the Clostridioides difficile Infections (Clostridium difficile Associated Disease) pipeline products market including Small Molecule, and Biologic.
Clostridioides difficile Infections (Clostridium difficile Associated Disease) overview
Clostridium difficile infections are caused by Clostridium difficile, often called C. difficile or “C. diff”, a bacterium that can cause symptoms ranging from diarrhea to life-threatening inflammation of the colon. Symptoms of C. diff infection include watery diarrhea with abdominal pain or tenderness, loss of appetite, fever, blood or pus in the stool, and weight loss. Risk factors are age, surgery of the gastrointestinal (GI) tract, a weakened immune system, kidney disease, use of proton-pump inhibitor medications, and use of chemotherapy drugs. This condition may be controlled by the use of medication such as antibiotics and may be prevented by lifestyle modification.
For a complete picture of Clostridioides difficile Infections (Clostridium difficile Associated Disease)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
